Last night, a Food and Drug Administration announced a capitulation of Kynamro, a new drug to reduce cholesterol in patients with homozygous patrimonial hypercholesterolemia (HoFH), a singular genetic illness that causes sky-high cholesterol levels and heart attacks during a immature age. The medicine, invented by Isis Pharmaceuticals, will be marketed by Genzyme, a rare-disease specialty section of Sanofi, a French drug giant.
As we minute a few weeks ago, when we dubbed Isis "biotech's misfortune winner," hopes for Kynamro have depressed significantly given we initial wrote about a drug 6 years ago. And there are liver side effects that could be really worrisome, and Kynamro injections can be painful. And it's taken a lot longer than people had expected. And
Read full article: http://www.guardian.co.uk/world/middle-east-live/2012/nov/20/gaza-conflict-ceasefire-talks-live
Source:
http://www.ezonearticle.com/2013/01/30/after-24-years-of-struggle-has-stan-crooke-finally-birthed-an-age-of-antisense/
0 comments:
Post a Comment